Great West Life Assurance Co. Can Sells 682 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Great West Life Assurance Co. Can reduced its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 2.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,004 shares of the medical research company’s stock after selling 682 shares during the quarter. Great West Life Assurance Co. Can’s holdings in Charles River Laboratories International were worth $4,529,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Arizona State Retirement System boosted its stake in Charles River Laboratories International by 0.3% in the 2nd quarter. Arizona State Retirement System now owns 14,090 shares of the medical research company’s stock valued at $3,015,000 after purchasing an additional 43 shares during the period. Wetherby Asset Management Inc. lifted its position in shares of Charles River Laboratories International by 2.5% during the 1st quarter. Wetherby Asset Management Inc. now owns 1,793 shares of the medical research company’s stock valued at $509,000 after acquiring an additional 44 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of Charles River Laboratories International by 1.6% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,121 shares of the medical research company’s stock valued at $668,000 after acquiring an additional 50 shares during the period. Cardinal Capital Management lifted its position in shares of Charles River Laboratories International by 0.7% during the 2nd quarter. Cardinal Capital Management now owns 7,717 shares of the medical research company’s stock valued at $1,651,000 after acquiring an additional 53 shares during the period. Finally, Cetera Investment Advisers lifted its position in shares of Charles River Laboratories International by 4.0% during the 2nd quarter. Cetera Investment Advisers now owns 1,478 shares of the medical research company’s stock valued at $316,000 after acquiring an additional 57 shares during the period. 97.80% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 2,279 shares of the company’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $249.90, for a total value of $569,522.10. Following the sale, the executive vice president now owns 2,499 shares in the company, valued at approximately $624,500.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 2,279 shares of the company’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $249.90, for a total value of $569,522.10. Following the sale, the executive vice president now owns 2,499 shares in the company, valued at approximately $624,500.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Joseph W. Laplume sold 6,409 shares of the company’s stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $224.25, for a total value of $1,437,218.25. Following the completion of the sale, the executive vice president now owns 20,232 shares in the company, valued at approximately $4,537,026. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,077 shares of company stock worth $2,334,821. Insiders own 1.10% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of CRL opened at $243.17 on Monday. Charles River Laboratories International, Inc. has a 12-month low of $181.36 and a 12-month high of $349.84. The business has a 50-day simple moving average of $226.53 and a two-hundred day simple moving average of $218.44. The company has a quick ratio of 1.14, a current ratio of 1.40 and a debt-to-equity ratio of 1.12. The stock has a market cap of $12.37 billion, a PE ratio of 28.64, a PEG ratio of 1.53 and a beta of 1.29.

Charles River Laboratories International (NYSE:CRLGet Rating) last issued its earnings results on Wednesday, November 2nd. The medical research company reported $2.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.51 by $0.12. Charles River Laboratories International had a return on equity of 20.93% and a net margin of 11.54%. The business had revenue of $989.16 million during the quarter, compared to analysts’ expectations of $978.65 million. Analysts anticipate that Charles River Laboratories International, Inc. will post 10.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CRL shares. StockNews.com started coverage on Charles River Laboratories International in a research report on Wednesday, October 12th. They set a “hold” rating for the company. Jefferies Financial Group downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, January 12th. JPMorgan Chase & Co. cut their target price on Charles River Laboratories International from $280.00 to $275.00 and set an “overweight” rating for the company in a research report on Thursday, November 3rd. William Blair reissued an “outperform” rating on shares of Charles River Laboratories International in a report on Wednesday, November 2nd. Finally, Credit Suisse Group lowered their price target on Charles River Laboratories International from $285.00 to $280.00 and set an “outperform” rating for the company in a report on Thursday, November 3rd. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $297.38.

Charles River Laboratories International Company Profile

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Read More

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.